Clinical
Supply & Demand
You can treat patients in a simple way using our technology
By directly measuring Cerebral Blood Flow, CoMind One gives the clinician direct feedback on whether efforts to increase CBF are succeeding. Utilising this feedback, Clinicians can optimise treatment strategies, precisely adjust interventions, and improve patient outcomes. Our technology offers real-time insights into cerebral autoregulation, enabling clinicians to identify and address brain physiology abnormalities promptly. The data that CoMind provides, allows clinicians to have better information to treat patients, and to know if their treatments are working. CoMind directly addresses critical needs identified by the Neurocritical Care Research Network, including continuous CBF monitoring and real-time autoregulation assessment.
The Fifth Neurocritical Care Research Network Conference's Proceedings and Recommendations [1] identified these as the top three most discussed area
1
Continuous measurement of cerebral autoregulation.
2
Optimal dosing for central nervous system acting medications.
3
Valid cerebral blood flow measurement at the bedside.
Cerebral Autoregulation is a fundamental function of the brain
Autoregulation is the ability of the brain to maintain CBF across a range of MAP to avoid both ischemia and hyperperfusion.
When autoregulation is intact, the brain can maintain proper CBF across a wide range of MAP, but when the brain is injured, its ability to autoregulate may be severely impaired. Thus the range of “safe MAP” may become dangerously restricted and unpredictable. Impaired autoregulation is a direct warning that brain physiology is abnormal. This should be of significant value to a clinician if it were readily available contemporaneously to treatment efforts.
Traumatic Brain injury
Intracranial pressure monitoring is
fundamental to critical care
Clinicians strive to match cerebral blood flow (CBF, supply) with cerebral metabolic rate of oxygen (CMRO2, demand) for optimal patient care. However, current technology cannot accurately measure this crucial balance across the entire care continuum. Existing methods rely on indirect and invasive procedures providing only generalised targets. This results in worse patient outcomes, increased healthcare costs, and limited adoption of current monitoring techniques.
Current Intracranial pressure (ICP) monitoring, while vital, is highly invasive, requiring surgical intervention. This leads to high costs, infection risks, and limited accessibility outside of ICU settings. ICP is an indirect measurement of cerebral perfusion, and the current method of CPP (MAP-ICP) is often inaccurate. The brain's ability to regulate CBF, cerebral autoregulation, is essential. Current monitoring fails to provide real-time insights into autoregulation, crucial for effective treatment.
Cardiac Surgery
Inadequate perfusion during cardiac surgery
CoMind's Clinical Advisory Board
The Clinical Advisory Board is composed of distinguished experts in the fields of neurology, neurosurgery, anesthesiology and critical care. Bringing decades of experience and a wealth of knowledge, these leaders provide independent broad-scope scientific and clinical guidance for the development and clinical application work being undertaken at CoMind.
Prof. John Gallagher
Clinical Advisory Board Member
Prof. Andrew Kofke
Clinical Advisory Board Member
Mary Kay Bader
Clinical Advisory Board Member
Dr. Howard Riina, MD
Clinical Advisory Board Member
Dr. Ramani Balu, MD
Clinical Advisory Board Member
Prof. Chris A Troianos
Clinical Advisory Board Member